ArticleMicrobial cell factories2026
Enhancing the bioconversion of phytosterols to 22-hydroxy-23,24- bisnorchol-4-ene-3-one in Mycobacterium neoaurum ZS-15 through genetic modification of kstD1 and wecA.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundC22 steroidal intermediates, including 22‑hydroxy‑23,24‑bisnorchol‑4‑ene‑3‑one (4‑HBC) and its Δ1‑dehydrogenated derivative 1,4‑HBC serve as key precursors for synthesizing progestational and adrenocortical hormones. However, the accumulation of multiple products coupled with the inherently poor cell permeability remains a critical challenge for producing high-purity and high-yield 4-HBC in Mycobacterium neoaurum, the most valuable producer for C22 steroidal intermediates. M. neoaurum ZS-15 is a promising cell factory accumulating high yield HBCs (90.67% 1,4-HBC, 8.11% 4-HBC) and minimal C19 by-products through transforming phytosterols (20 g/L). In order to enhance the industrial potential of ZS-15, we first identified the key 3-ketosteroid-Δ1-dehydrogenase (KstD) which is responsible for catalyzing 4-HBC to produce 1,4-HBC. Then, it was knocked out by a modified gene editing system constructed in this study. Subsequently, we achieved the aim of improving cell permeability and promoting the product titer through the strategy of inhibiting a cell wall synthesis-related gene.
resultsIn this work, KstD1 was predicted (by molecular docking) and confirmed (via CRISPR/dCas9-mediated knockdown) as the key isoenzyme for converting 4-HBC to 1,4-HBC in ZS-15. A modified CRISPR/Cas12a gene editing system (pRH2502-FnCpf1cg and pCR-Hyg-tetO) tailored for ZS-15 was developed through promoter substitution and plasmid backbone fusion, and a kstD1 knockout strain (M-ΔkstD1), which increased 4-HBC proportion in the product to 96.00% (at 20 g/L phytosterols), was constructed. The knockdown of three cell wall synthesis-related genes revealed that inhibiting the expression of N-acetylglucosamine-1-phosphate transferase (M-iwecA) led to the largest increase in 1,4-HBC titer relative to ZS-15, despite causing slight reductions in growth rate and biomass. Consequently, the highest 4-HBC titer at flask scale (28.80 g/L from 40 g/L phytosterols) was achieved by strain M-ΔkstD1-iwecA via combinatorial engineering of kstD1 knockout and wecA knockdown, attaining a 95% molar yield and 93.12% purity.
conclusionsOur study demonstrates that inhibition of wecA significantly enhances cell permeability, thereby improving phytosterol utilization efficiency in ZS-15, and knockout of kstD1 results in the main product converting to 4-HBC from 1,4-HBC. These findings provide a robust foundation for developing high-yield 4-HBC production systems and offer novel metabolic engineering strategies for steroid intermediate biosynthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.